These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 1419825)

  • 1. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
    Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
    Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
    Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
    Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
    Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
    Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH; Hoffbrand AV; Sheikh-Taha M; Koussa S; Khoriaty AI; Taher A
    Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N; Jahazi A; Rahim Abad HH
    Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.